M. E. Scheulen

7.2k citations

178 papers · 5.5k indexed · 1 hit paper · h-index 36

Impact in

Oncology top 1%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
Hematology top 2%

Papers in

Oncology 99
- Cancer Treatment and Pharmacology 38
- Colorectal Cancer Treatments and Studies 24
- Pancreatic and Hepatic Oncology Research 11
Hematology 19

Co-authors: Dirk Strumberg Ralf A. Hilger S. Seeber Heike Richly H. Kappus D. Voliotis K. Mross Brian Schwartz
Journals: Journal of Clinical Oncology (31 papers)Journal of Cancer Research and Clinical Oncology (13 papers)Cancer Treatment Reviews (7 papers)Annals of Oncology (7 papers)British Journal of Cancer (7 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

M. E. Scheulen

174 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors 2004 · 694 citations

Peers

Countries citing papers authored by M. E. Scheulen

Since Specialization

Citations

This map shows the geographic impact of M. E. Scheulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Scheulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Scheulen more than expected).

Fields of papers citing papers by M. E. Scheulen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Scheulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Scheulen. The network helps show where M. E. Scheulen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside M. E. Scheulen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. E. Scheulen Line = papers co-authored together M. E. Scheulen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors British Journal of Cancer ·Sebastian Bauer, Xu PeiFang, Thomas Mühlenberg, Florian Grabellus, James Nagarajah, Mathias Hoiczyk, Annette Reichardt, Marit Ahrens, Peter Reichardt, Susanne Grünewald, M. E. Scheulen, Soohyen Jang, E Bock, Martin Schüler, Daniel Pink	2014	39
2	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas European Journal of Cancer ·Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park, Chung‐Pin Li, M. E. Scheulen, 辰雄西成, Do‐Youn Oh, Yuan Liu, Suman Redhu, Klaudia Steplewski, Ngocdiep T. Le	2014	271
3	First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors PLoS ONE ·K. Mross, Heike Richly, Richard Fischer, Qiqi Liao, Martin Büchert, 五條しおり, Hendrik Gille, Laurent Audoly, M. E. Scheulen	2013	41
4	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors Clinical Cancer Research ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, Fan Weiyan, Xiaofei Gao, Jan H.M. Schellens, Wilfried Eberhardt	2012	55
5	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses Journal of Hepatology ·Jean‐Luc Raoul, Jordi Bruix, Tim F. Greten, Morris Sherman, Vincenzo Mazzaferro, Philip Hilgard, Hans Scherübl, M. E. Scheulen, Georgios Germanidis, Sophie Dominguez, Sergio Ricci, Andrea Nadel, M. Moscovici, D. Voliotis, Josep M. Llovet	2012	102
6	A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Ruth Plummer, Ayman Madi, B Roberts, Heike Richly, Yulian Zhang, Stephen D. Rubin, Howard Ball, Steve Weller, Jeffrey Botbyl, D. Gibson, M. E. Scheulen	2012	25
7	Transarterial Hepatic Chemoperfusion of Uveal Melanoma Metastases: Survival and Response to Treatment RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren ·Till A. Heusner, Gerald Antoch, G. Tagliaferri, S. Ladd, Michael Forsting, Yan Hong Ru, M. E. Scheulen	2011	20
8	Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group) Investigational New Drugs ·Beate Schultheis, Dirk Strumberg, Lothar Bergmann, Ullrich Graeven, Axel-Rainer Hanauske, Rainer W. Lipp, Jochen Schuette, Kaku Saito, P. Scigalla, M. E. Scheulen	2011	12
9	Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, M. E. Scheulen, Ralf A. Hilger, Juergen Krauss, Norbert Marschner, Florian Lordick, F. Bach, Dirk Reuter, Lutz Edler, Sile Yu	2010	12
10	Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma Melanoma Research ·Alexander Schmittel, M. E. Scheulen, Nikolaos E. Bechrakis, Dirk Strumberg, Joachim Baumgart, Norbert Bornfeld, Michael Foerster, E. Thiel, Ulrich Keilholz	2005	40
11	Ernährung, Lifestyle und Krebs: Wege zur Primärprävention DMW - Deutsche Medizinische Wochenschrift ·Dirk Strumberg, Heiner Boeing, M. E. Scheulen, H Förster, S. Seeber	2004	1
12	Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications Bone Marrow Transplantation ·Dietrich W. Beelen, Rudolf Trenschel, J. Casper, Mathias Freund, Ralf A. Hilger, M. E. Scheulen, Nadežda Basara, A. A. Fauser, Bernd Hertenstein, T.C. Lu, Joachim Baumgart, Uwe Pichlmeier, J. Hahn, Ernst Holler	2004	84
13	Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR) Anti-Cancer Drugs ·K. Mross, M. E. Scheulen, Thomas Licht, Clemens Unger, Heike Richly, 五條しおり, Klaus Kutz, 宮下卓也, Paola Barbieri, Leticia Santos Avila Constâncio, Bruno Vincenzi, A. Bernareggi	2004	3
14	Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia Experimental Hematology ·Sabine Kasimir‐Bauer, Dietrich W. Beelen, Michael Flaßhove, Richard Noppeney, S. Seeber, M. E. Scheulen	2002	29
15	High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer Journal of Cancer Research and Clinical Oncology ·Peter Bojko, M. E. Scheulen, Ralf A. Hilger, C. Oberhoff, Adolf E. Schindler, S. Seeber	2001	8
16	Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Ralf A. Hilger, A. Harstrick, Wilfried Eberhardt, C. Oberhoff, Dina Kurmangalieva, Joachim Baumgart, S. Seeber, M. E. Scheulen	1998	55
17	Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusion—an experimental study in dogs European Journal of Surgical Oncology ·Thomas Pfeiffer, U. Krause, Yiming Chen, Andrzej Rajewski, L. Kałuska, M. E. Scheulen	1997	8
18	A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer Oncology Research and Treatment ·A. Harstrick, Hans‐Joachim Wilke, Wilfried Eberhardt, U. Klaassen, Dirk Strumberg, Michael Korn, M. E. Scheulen, Joachim Baumgart, S. Seeber	1996	20
19	Development of drug derivatives without cross-resistance to parent compounds Cancer Treatment Reviews ·M. E. Scheulen	1990	1
20	[Effect of 2-hydroxyestradiol-17beta on NADPH-dependent electron transfer in rat liver microsomes in vitro (author's transl)]. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Peter Wollenberg, M. E. Scheulen, Xiao Wen Luah, H. Kappus, H. Remmer	1976	4

About M. E. Scheulen

M. E. Scheulen is a scholar working on Oncology, Hematology, Cancer Research, Pulmonary and Respiratory Medicine and Ophthalmology, having authored 178 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (38 papers), Colorectal Cancer Treatments and Studies (24 papers), Cancer therapeutics and mechanisms (17 papers), Melanoma and MAPK Pathways (13 papers), Chemotherapy-induced cardiotoxicity and mitigation (12 papers), Pancreatic and Hepatic Oncology Research (11 papers), Testicular diseases and treatments (11 papers) and Gastric Cancer Management and Outcomes (10 papers). The work is most often cited by research in Oncology (2.6k citations), Hematology (597 citations), Hepatology (390 citations), Cancer Research (734 citations) and Internal Medicine (153 citations). M. E. Scheulen has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dirk Strumberg, Ralf A. Hilger, S. Seeber, Heike Richly, H. Kappus, D. Voliotis, K. Mross, Brian Schwartz, E. Brendel and R. Voigtmann. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cancer Research and Clinical Oncology, Cancer Treatment Reviews, Annals of Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact